Contineum Therapeutics, Inc. Class A Common Stock (CTNM NASDAQ) stock market data APIs
$12.3065
-0.04(-0.3%)
as of September 18, 2025
Try our APIs with
free plan!
Contineum Therapeutics, Inc. Class A Common Stock Financial Data Overview
Price chart is built with
Anychart
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Prev. Close
12.3065
Open
12.2616
High
12.6054
Low
11.9769
52 wk Range
3.35-20.3
Market Cap
347 M
Shares Outstanding
21 625 K
EPS
-0.62
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Contineum Therapeutics, Inc. Class A Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Contineum Therapeutics, Inc. Class A Common Stock data using free add-ons & libraries
Get Contineum Therapeutics, Inc. Class A Common Stock Fundamental Data
Contineum Therapeutics, Inc. Class A Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -65 738 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Contineum Therapeutics, Inc. Class A Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: -0.28
Get Contineum Therapeutics, Inc. Class A Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Contineum Therapeutics, Inc. Class A Common Stock News
New
Contineum Therapeutics Reports Positive Topline Data From PIPE-791 Phase 1b PET Trial
(RTTNews) - Contineum Therapeutics, Inc. (CTNM) on Thursday announced positive topline data from its PIPE-791 Phase 1b positron emission tomography (PET) trial, which met its primary endpoint. The Ph...
Contineum Therapeutics Non-GAAP EPS of -$0.62
* Contineum Therapeutics press release [https://seekingalpha.com/pr/20190078-contineum-therapeutics-reports-second-quarter-2025-financial-results-updates-key-clinical] (NASDAQ:CTNM [https://seekinga...
Contineum (CTNM) Q2 R&D Jumps 78%
Key Points GAAP net loss per share widened to $(0.62) in Q2 2025, missing analyst GAAP EPS estimates by $0.18, driven by a sharp rise in research and development expenses. R&D expenses surged 78%, re...
Contineum completes enrollment in Phase 1b PET trial cohorts
SAN DIEGO - Contineum Therapeutics (NASDAQ:CTNM), a clinical-stage biotech currently trading at $4.53 and according to InvestingPro analysis showing signs of being overvalued, has completed enrollment...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
